Neurotech International Limited

Neurotech International Limited is a clinical-stage biopharmaceutical company specializing in the research, development, and manufacture of medical devices and pharmaceutical therapies focused on paediatric neurological disorders. Its primary asset is NTI164, a proprietary broad-spectrum oral cannabinoid therapy developed for conditions such as Autism Spectrum Disorder (ASD), Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), Rett Syndrome, and spastic cerebral palsy. Neurotech International conducts advanced clinical trials to assess NTI164’s neuroprotective, anti-inflammatory, and neuro-modulatory properties, and has reported clinically meaningful and statistically significant benefits in several indications. The company also developed Mente, a home-use medical device designed to aid engagement and relaxation in autistic children with elevated delta band brain activity. Headquartered in Melbourne, Australia and established in 2016, Neurotech International plays a notable role in bringing innovative therapies to pediatric neurology and contributes to ongoing advancements in cannabinoid-based drug development within the healthcare sector.